SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. (Q34194226)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

title

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

S Hart

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

K C Goh

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

V Novotny-Diermayr

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

C Y Hu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

H Hentze

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Y C Tan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

B Madan

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

C Amalini

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Y K Loh

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

L C Ong

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

A D William

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

A Lee

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

R Jayaraman

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

K H Ong

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

K Ethirajulu

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

B W Dymock

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

J W Wood

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

publication date

21 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

1751-1759

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2011.148

5 February 2020

exact match

0 references

cites work

The JAK/STAT signaling pathway

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

Recent advances in the bcr-abl negative chronic myeloproliferative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

Emerging Flt3 kinase inhibitors in the treatment of leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

The exploration of macrocycles for drug discovery--an underexploited structural class

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

Activated Jak2 with the V617F point mutation promotes G1/S phase transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

TACE is required for the activation of the EGFR by TGF-alpha in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

How I treat myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

Through the "gatekeeper door": exploiting the active kinase conformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

Staging and evaluation of the patient with lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

SOCS2: inhibitor of JAK2V617F-mediated signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

The myeloproliferative disorder associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.148

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2011.148

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

5 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691275%20AND%20SRC:MED&resulttype=core&format=json